SHAREHOLDER TOOLS


Briefcase Printed Materials Email Alerts Download Center snapshot RSS


STOCK INFORMATION

NASDAQ: ELGX
Price:
10.91
Change:
- 0.24
Volume:
90,264
11:12 AM ET on May 4, 2016
Delayed at least 20min, by eSignal

2014 Annual Report

2014 Annual Report
(PDF - 2.29 MB)

Investor Presentation - February 2016


(PDF - 2.2 MB)

Investor Relations


May 9, 2016
5:00 PM ET

Endologix 2016 First Quarter Financial Results Conference Call
Webcast    Webcast


Jan 12, 2016
8:00 AM PT

J.P. Morgan Healthcare Conference
Webcast    Webcast
PDF View Presentation  2.2 MB   Add to Briefcase


ASCEND Registry Presentation - Charing Cross 2016
Global Registry Podium Charing Cross 2016
Anatomic Fixation and ActiveSeal:
The Decades of Advancements in
Endovascular AAA Repair

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

Addressing a significant medical problem. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age.

Superior, patented design. The technology is a minimally invasive device, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Covered by 18 U.S. patents with 393 allowed claims, the technology is designed to overcome the significant shortcomings of first-generation ELGs.

Compelling clinical data. There is a significant reduction in blood loss, operative time, Intensive Care Unit (ICU) utilization and hospital length of stay for Powerlink patients when compared with traditional open surgical repair for AAA. Also, on-going clinical study results show there is a lower mortality for Powerlink patients than in open surgical repair patients.

Seasoned management team. The executive management team has a record of building shareholder value with over 175 years of combined medical device experience and a strong record of success with medical products.

RSS   View all news releasesRECENT RELEASES

Apr 29, 2016

Endologix to Participate in Two Investor Conferences in May

Apr 28, 2016

Positive Nellix Clinical Data from the ASCEND Study for the Treatment of Juxta and Pararenal AAA Presented at the 38th Annual Charing Cross Symposium

Apr 27, 2016

Positive Nellix Clinical Data from the Global Registry and Treatment of Iliac Aneurysm Studies Presented at the 38th Annual Charing Cross Symposium


View all eventsUPCOMING EVENTS

May 5, 2016 at 11:20 AM ET

Deutsche Bank 41st Annual Health Care Conference

May 5, 2016 at 11:20 AM ET

Deutsche Bank 41st Annual Health Care Conference

Copyright © 2011 Endologix, Inc. All Rights Reserved. - Save to PDF